These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 38375157)

  • 21. Identification and Validation of T-Cell Exhaustion Signature for Predicting Prognosis and Immune Response in Pancreatic Cancer by Integrated Analysis of Single-Cell and Bulk RNA Sequencing Data.
    Zhu Y; Tan L; Luo D; Wang X
    Diagnostics (Basel); 2024 Mar; 14(6):. PubMed ID: 38535087
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel immunogenomic signature to predict prognosis and reveal immune infiltration characteristics in pancreatic ductal adenocarcinoma.
    Li A; Ye B; Lin F; Wang Y; Miao X; Jiang Y
    Precis Clin Med; 2022 Jun; 5(2):pbac010. PubMed ID: 35694712
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Determination of a DNA repair-related gene signature with potential implications for prognosis and therapeutic response in pancreatic adenocarcinoma.
    Lai J; Chen W; Zhao A; Huang J
    Front Oncol; 2022; 12():939891. PubMed ID: 36353555
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pancreatic adenocarcinoma associated immune-gene signature as a novo risk factor for clinical prognosis prediction in hepatocellular carcinoma.
    Dai L; Mugaanyi J; Cai X; Lu C; Lu C
    Sci Rep; 2022 Jul; 12(1):11944. PubMed ID: 35831362
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comprehensive characterization of extracellular matrix-related genes in PAAD identified a novel prognostic panel related to clinical outcomes and immune microenvironment: A silico analysis with
    Chen X; Yuan Q; Liu J; Xia S; Shi X; Su Y; Wang Z; Li S; Shang D
    Front Immunol; 2022; 13():985911. PubMed ID: 36311789
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel sphingolipid metabolism-related long noncoding RNA signature predicts the prognosis, immune landscape and therapeutic response in pancreatic adenocarcinoma.
    He X; Xu Z; Ren R; Wan P; Zhang Y; Wang L; Han Y
    Heliyon; 2024 Jan; 10(1):e23659. PubMed ID: 38173505
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Crosstalk of ferroptosis regulators and tumor immunity in pancreatic adenocarcinoma: novel perspective to mRNA vaccines and personalized immunotherapy.
    Shi Y; Wang Y; Dong H; Niu K; Zhang W; Feng K; Yang R; Zhang Y
    Apoptosis; 2023 Oct; 28(9-10):1423-1435. PubMed ID: 37369808
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development and validation of a novel ferroptosis‑related lncRNA prognostic signature for pancreatic adenocarcinoma.
    Li J; Li W; Wang H; Ni B; Liu Y
    Mol Med Rep; 2023 Feb; 27(2):. PubMed ID: 36660936
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identify potential prognostic indicators and tumor-infiltrating immune cells in pancreatic adenocarcinoma.
    Shi T; Gao G
    Biosci Rep; 2022 Feb; 42(2):. PubMed ID: 35083488
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mitochondrial energy metabolism-related gene signature as a prognostic indicator for pancreatic adenocarcinoma.
    Ma Y; Tang R; Huang P; Li D; Liao M; Gao S
    Front Pharmacol; 2024; 15():1332042. PubMed ID: 38572434
    [No Abstract]   [Full Text] [Related]  

  • 31. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
    Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
    Front Immunol; 2021; 12():693062. PubMed ID: 34497605
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of Prognostic Immune-Related Genes in Pancreatic Adenocarcinoma and Establishment of a Prognostic Nomogram: A Bioinformatic Study.
    Wu G; Deng Z; Jin Z; Wang J; Xu B; Zeng J; Peng M; Wen Z; Guo Y
    Biomed Res Int; 2020; 2020():1346045. PubMed ID: 32596278
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exploring the significance of novel immune-related gene signatures in the prognosis and immune features of pancreatic adenocarcinoma.
    Chen B; Hu C; Jiang L; Xiang Z; Zuo Z; Lin Y; Liu C
    Int Immunopharmacol; 2021 Mar; 92():107359. PubMed ID: 33465729
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification and validation of a novel cuproptosis signature for stratifying different prognostic, immune, metabolic, and therapeutic landscapes in pancreatic adenocarcinoma.
    Yan X; Zheng W; Xu FS; Chang HL; Zhang Y; Zhang ZY; Zhang YH
    Eur Rev Med Pharmacol Sci; 2024 Mar; 28(5):2024-2050. PubMed ID: 38497885
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of tumor antigens and immune subtypes of pancreatic adenocarcinoma for mRNA vaccine development.
    Huang X; Zhang G; Tang T; Liang T
    Mol Cancer; 2021 Mar; 20(1):44. PubMed ID: 33648511
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comprehensive Analysis of 5-Methylcytosine (m
    Wang R; Guo Y; Ma P; Song Y; Min J; Zhao T; Hua L; Zhang C; Yang C; Shi J; Zhu L; Gan D; Li S; Li J; Su H
    Front Oncol; 2022; 12():851766. PubMed ID: 35433474
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Construction of a pancreatic cancer prediction model for oxidative stress-related lncRNA.
    Huang H; Wei Y; Yao H; Chen M; Sun J
    Funct Integr Genomics; 2023 Apr; 23(2):118. PubMed ID: 37020128
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Construction of an efferocytosis-related long non-coding ribonucleic acid scoring system to predict clinical outcome and immunotherapy response in pancreatic adenocarcinoma.
    Zhou C; Gan X; Sun S; Wang L; Zhang Y; Zhang J
    Biochem Biophys Rep; 2023 Sep; 35():101540. PubMed ID: 37692763
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship between a 7-mRNA signature of the pancreatic adenocarcinoma microenvironment and patient prognosis (a STROBE-compliant article).
    He QL; Jiang HX; Zhang XL; Qin SY
    Medicine (Baltimore); 2020 Jul; 99(29):e21287. PubMed ID: 32702921
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Machine learning-based identification of biomarkers and drugs in immunologically cold and hot pancreatic adenocarcinomas.
    Ge J; Ge J; Tang G; Xiong D; Zhu D; Ding X; Zhou X; Sang M
    J Transl Med; 2024 Aug; 22(1):775. PubMed ID: 39152432
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.